These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 26173185)

  • 21. Bridging Solutions in Dose Finding Problems.
    O'Quigley J; Iasonos A
    Stat Biopharm Res; 2014 May; 6(2):185-197. PubMed ID: 25071878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.
    Rinaldi DA; Burris HA; Dorr FA; Woodworth JR; Kuhn JG; Eckardt JR; Rodriguez G; Corso SW; Fields SM; Langley C
    J Clin Oncol; 1995 Nov; 13(11):2842-50. PubMed ID: 7595747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials.
    Tighiouart M; Li Q; Piantadosi S; Rogatko A
    Am J Biostat; 2016; 6(1):1-11. PubMed ID: 28706582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials.
    Gönen M
    Contemp Clin Trials; 2005 Apr; 26(2):131-40. PubMed ID: 15837436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study.
    Zohar S; Resche-Rigon M; Chevret S
    Clin Trials; 2013; 10(3):414-21. PubMed ID: 21824977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bayesian optimization for estimating the maximum tolerated dose in Phase I clinical trials.
    Takahashi A; Suzuki T
    Contemp Clin Trials Commun; 2021 Mar; 21():100753. PubMed ID: 33681528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A statistical evaluation of dose expansion cohorts in phase I clinical trials.
    Boonstra PS; Shen J; Taylor JM; Braun TM; Griffith KA; Daignault S; Kalemkerian GP; Lawrence TS; Schipper MJ
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25710960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incorporating Historical Data in Bayesian Phase I Trial Design: The Caucasian-to-Asian Toxicity Tolerability Problem.
    Takeda K; Morita S
    Ther Innov Regul Sci; 2015 Jan; 49(1):93-99. PubMed ID: 30222449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Phase I cancer trials methodology].
    Le Tourneau C; Faivre S; Raymond E; Diéras V
    Bull Cancer; 2007 Nov; 94(11):943-51. PubMed ID: 18055311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric oncology drug development and dosage optimization.
    Cheung SYA; Hay JL; Lin YW; de Greef R; Bullock J
    Front Oncol; 2023; 13():1235947. PubMed ID: 38348118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
    Tighiouart M; Rogatko A; Babb JS
    Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized phase I Bayesian dose escalation design for the combination of anti-cancer drugs.
    Dejardin D; Lesaffre E; Hamberg P; Verweij J
    Pharm Stat; 2014; 13(3):196-207. PubMed ID: 24715683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. np1: a computer program for dose escalation strategies in phase I clinical trials.
    Kramar A; Houédé N; Paoletti X
    Comput Methods Programs Biomed; 2007 Oct; 88(1):8-17. PubMed ID: 17719124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incoherent dose-escalation in phase I trials using the escalation with overdose control approach.
    Wheeler GM
    Stat Pap (Berl); 2018 Jun; 59(2):801-811. PubMed ID: 29875549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A two-stage dose selection strategy in phase I trials with wide dose ranges.
    Wang O; Faries DE
    J Biopharm Stat; 2000 Aug; 10(3):319-33. PubMed ID: 10959914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I Designs that Allow for Uncertainty in the Attribution of Adverse Events.
    Iasonos A; O'Quigley J
    J R Stat Soc Ser C Appl Stat; 2017 Nov; 66(5):1015-1030. PubMed ID: 29085158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial.
    Huang B; Kuan PF
    Biom J; 2014 Nov; 56(6):933-46. PubMed ID: 24895140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using the continual reassessment method: lessons learned from an EORTC phase I dose finding study.
    Paoletti X; Baron B; Schöffski P; Fumoleau P; Lacombe D; Marreaud S; Sylvester R
    Eur J Cancer; 2006 Jul; 42(10):1362-8. PubMed ID: 16740385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-stage design for phase I-II cancer clinical trials using continuous dose combinations of cytotoxic agents.
    Tighiouart M
    J R Stat Soc Ser C Appl Stat; 2019 Jan; 68(1):235-250. PubMed ID: 30745708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.